Our site is slower due to heavy traffic from automated ’bots’ and AI crawlers. We’re working to fix this. Read more here.

Robert Israel, MD

Title(s)Professor of Obstetrics & Gynecology
SchoolKeck School of Medicine of Usc
AddressIRD 501 2020 Zonal
Off Campus
Los Angeles CA 90033
Phone+1 626 808 5261
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Robert Israel, M.D., graduated with a BA in English and Anthropology from Harvard College, an MD from the University of Pennsylvania School of Medicine, and a residency in Obstetrics and Gynecology at The Johns Hopkins Hospital. He completed a post-residency, two-year obligation to the US Navy in the Department of Obstetrics and Gynecology at Balboa Naval Hospital in San Diego, California, where he established the first Infertility Clinic. He joined the new, full-time Department of Obstetrics and Gynecology at the University of Southern California (USC) School of Medicine in late 1969, and has remained a faculty member at that institution ever since, achieving professorial level. He has been a member of the department’s Executive Committee, since its inception in 1970. For over 25 years, he was the director of the department’s required medical student rotation. He chaired the division of gynecology at two different times for over 10 years. From 2005 -2007, he was the first director of development for the department. During that time period, he initiated two endowed department chairs and helped convert the department’s former resident organization into a significant alumni association. Presently, he is the chair of quality improvement for the department and director of the women’s health clinics. Nationally, he belongs to the Pacific Coast Reproductive Society and was its President in 1980, the American Society of Reproductive Medicine, the American College of Obstetricians and Gynecologists, and the Pacific Coast Obstetrical and Gynecological Society, having been its President in 2002 and, presently, the Chair of the Society’s Industry Liaison Committee. He has authored multiple, peer-reviewed publications, as well as book chapters. His medical interests include endometriosis, reproductive problems, myomata uteri, sterilization, intrauterine adhesions, and uterine congenital anomalies. Dr. Israel’s outside interests include the completion of ten marathons and classical theater, epitomized by his third appointment to the Board of Directors of A Noise Within, the classical repertory theater in the Los Angeles area.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Clinico-Virological Outcomes and Mutational Profile of SARS-CoV-2 in Adults Treated with Ribavirin Aerosol for COVID-19 Pneumonia. Microorganisms. 2024 Jun 05; 12(6). Morsica G, Messina E, Bagaglio S, Galli L, Lolatto R, Sampaolo M, Barakat M, Israel RJ, Castagna A, Clementi N. PMID: 38930529; PMCID: PMC11205916.
      View in: PubMed   Mentions:
    2. Impact of Patient Subgroups on the Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients with Advanced Illness. J Pain Res. 2023; 16:3529-3543. Mehta N, Slatkin NE, Israel RJ, Stambler N, Shah ED. PMID: 37881233; PMCID: PMC10595216.
      View in: PubMed   Mentions:
    3. Methylnaltrexone Treatment for Opioid-Induced Constipation in Patients with and without Cancer: Effect of Initial Dose. J Pain Res. 2023; 16:2595-2607. Chamberlain BH, Rhiner M, Slatkin NE, Stambler N, Israel RJ. PMID: 37533563; PMCID: PMC10391063.
      View in: PubMed   Mentions: Translation:CTClinical Trials
    4. Reductions in All-Cause Mortality Associated with the Use of Methylnaltrexone for Opioid-Induced Bowel Disorders: A Pooled Analysis. Pain Med. 2023 Mar 01; 24(3):341-350. Webster LR, Brenner D, Israel RJ, Stambler N, Slatkin NE. PMID: 36102822; PMCID: PMC9977130.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    5. Subcutaneous Methylnaltrexone as Treatment for Opioid-Induced Constipation in Patients with Advanced Cancer and Noncancer Illnesses: A Post Hoc Analysis of Two Clinical Trials. J Pain Res. 2023; 16:395-406. Shah ED, Chamberlain BH, Rhiner M, Slatkin NE, Stambler N, Israel RJ. PMID: 36798078; PMCID: PMC9926929.
      View in: PubMed   Mentions:
    6. Cumulative Laxation Response with Methylnaltrexone: Implications for Hospitalized Patients with Advanced Illness and Opioid-Induced Constipation. Curr Ther Res Clin Exp. 2023; 98:100694. Farchadi D, Slatkin NE, Stambler N, Israel RJ, Matus M. PMID: 36875317; PMCID: PMC9981808.
      View in: PubMed   Mentions:    Fields:    
    7. A Randomized, Double-Blind, Parallel Design Thorough QT Study With a Nested Crossover to Compare the Cardiac Safety of Amiselimod With Placebo and Positive Control in Healthy Volunteers. Clin Pharmacol Drug Dev. 2023 03; 12(3):236-248. Lee J, Lester R, O'Reilly T, Lowe ER, Slatkin NE, Franklin H, Israel RJ. PMID: 36708138.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. Ribavirin aerosol in hospitalized adults with respiratory distress and COVID-19: An open-label trial. Clin Transl Sci. 2023 01; 16(1):165-174. Poulakou G, Barakat M, Israel RJ, Bacci MR, Virazole Collaborator Group for COVID-19 Respiratory Distress. PMID: 36326174; PMCID: PMC9841304.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    9. A randomized, placebo-controlled study to evaluate safety and pharmacokinetics of inhaled ribavirin. Clin Transl Sci. 2022 09; 15(9):2159-2171. Couroux P, Brkovic A, Vittitow JL, Israel RJ, Pamidi C, Patel J, Barakat M. PMID: 35677972; PMCID: PMC9468560.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    10. Dosing of Rifaximin Soluble Solid Dispersion Tablets in Adults With Cirrhosis: 2 Randomized, Placebo-controlled Trials. Clin Gastroenterol Hepatol. 2023 03; 21(3):723-731.e9. Bajaj JS, Hassanein TI, Pyrsopoulos NT, Sanyal AJ, Rahimi RS, Heimanson Z, Israel RJ, Rockey DC. PMID: 35750249.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    11. First-Dose Efficacy of Methylnaltrexone in Patients with Severe Medical Illness and Opioid-Induced Constipation: A Pooled Analysis. J Emerg Med. 2022 Feb; 62(2):231-239. Peacock WF, Slatkin NE, Israel RJ, Stambler N. PMID: 34893381.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    12. P029 Pharmacokinetic/Pharmacodynamic Analysis of Amiselimod, a Selective Sphingosine 1-Phosphate Receptor Modulator, in Healthy Subjects: Results From a Phase 1 Study. Am J Gastroenterol. 2021 Dec 01; 116(Suppl 1):S7. Lee J, Lester R, O'Reilly T, Lowe E, Slatkin N, Franklin H, Israel R. PMID: 37461948.
      View in: PubMed   Mentions: 1     Fields:    
    13. Attrition of methylnaltrexone treatment-emergent adverse events in patients with chronic noncancer pain and opioid-induced constipation: a post hoc pooled analysis of two clinical trials. F1000Res. 2021; 10:891. Mehta N, Slatkin NE, Israel RJ, Stambler N. PMID: 34631030; PMCID: PMC8485099.
      View in: PubMed   Mentions: 1     Fields:    
    14. Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Cancer versus Noncancer Patients: An Analysis of Efficacy and Safety Variables from Two Studies. J Pain Res. 2021; 14:2687-2697. Chamberlain BH, Rhiner M, Slatkin NE, Stambler N, Israel RJ. PMID: 34512008; PMCID: PMC8420564.
      View in: PubMed   Mentions: 4  
    15. Ribavirin Aerosol in the Treatment of SARS-CoV-2: A Case Series. Infect Dis Ther. 2021 Dec; 10(4):2791-2804. Messina E, Danise A, Ferrari G, Andolina A, Chiurlo M, Razanakolona M, Barakat M, Israel RJ, Castagna A. PMID: 34302258; PMCID: PMC8302211.
      View in: PubMed   Mentions: 6  
    16. The influence of brain metastases on the central nervous system effects of methylnaltrexone: a post hoc analysis of 3 randomized, double-blind studies. Support Care Cancer. 2021 Sep; 29(9):5209-5218. Brenner DM, Slatkin NE, Stambler N, Israel RJ, Coluzzi PH. PMID: 33629189; PMCID: PMC8295095.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    17. Malignancy Rates in Brodalumab Clinical Studies for Psoriasis. Am J Clin Dermatol. 2020 Jun; 21(3):421-430. Gottlieb A, Lebwohl M, Liu C, Israel RJ, Jacobson A. PMID: 32207067; PMCID: PMC7275023.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    18. Subcutaneous methylnaltrexone for opioid-induced constipation in advanced-illness patients with or without active cancer. Pain Manag. 2020 Mar; 10(2):73-84. Chamberlain BH, Rhiner M, Slatkin NE, Stambler N, Israel RJ. PMID: 31951150.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    19. Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study. Am J Clin Dermatol. 2019 Dec; 20(6):863-871. Lebwohl MG, Blauvelt A, Menter A, Papp KA, Guenthner S, Pillai R, Israel RJ, Jacobson A. PMID: 31493163; PMCID: PMC6872506.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    20. Immunogenicity and skin clearance recapture in clinical studies of brodalumab. J Am Acad Dermatol. 2020 Feb; 82(2):344-351. Bagel J, Lebwohl M, Israel RJ, Jacobson A. PMID: 31175910.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    21. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials. Br J Dermatol. 2019 02; 180(2):306-314. Langley RG, Armstrong AW, Lebwohl MG, Blauvelt A, Hsu S, Tyring S, Rastogi S, Pillai R, Israel R. PMID: 30328108.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    22. Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain. J Pain Res. 2019; 12:139-150. Rauck RL, Slatkin NE, Stambler N, Israel RJ. PMID: 30613162; PMCID: PMC6307492.
      View in: PubMed   Mentions: 3  
    23. Oral methylnaltrexone is efficacious and well tolerated for the treatment of opioid-induced constipation in patients with chronic noncancer pain receiving concomitant methadone. J Pain Res. 2018; 11:2509-2516. Webster LR, Israel RJ. PMID: 30425563; PMCID: PMC6205130.
      View in: PubMed   Mentions: 1  
    24. Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019 Jan; 80(1):282-285. Lebwohl MG, Sugarman JL, Gold LS, Pariser DM, Lin T, Pillai R, Martin G, Harris S, Israel R. PMID: 30227193.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    25. Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain. J Pain Res. 2018; 11:1503-1510. Webster LR, Israel RJ. PMID: 30147355; PMCID: PMC6095122.
      View in: PubMed   Mentions: 6  
    26. Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome. Gut Microbes. 2019; 10(1):22-33. Fodor AA, Pimentel M, Chey WD, Lembo A, Golden PL, Israel RJ, Carroll IM. PMID: 29708822; PMCID: PMC6363070.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    27. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018 08; 179(2):320-328. Papp KA, Gordon KB, Langley RG, Lebwohl MG, Gottlieb AB, Rastogi S, Pillai R, Israel RJ. PMID: 29488226.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    28. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2018 Aug; 79(2):287-293. Gold LS, Lebwohl MG, Sugarman JL, Pariser DM, Lin T, Martin G, Pillai R, Israel R, Ramakrishna T. PMID: 29614243.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    29. Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018 Jan; 78(1):81-89.e5. Lebwohl MG, Papp KA, Marangell LB, Koo J, Blauvelt A, Gooderham M, Wu JJ, Rastogi S, Harris S, Pillai R, Israel RJ. PMID: 28985956.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    30. Long-Term Safety and Efficacy of Subcutaneous Methylnaltrexone in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain: A Phase 3, Open-Label Trial. Pain Med. 2017 Aug 01; 18(8):1496-1504. Webster LR, Michna E, Khan A, Israel RJ, Harper JR. PMID: 28810695; PMCID: PMC5914419.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    31. Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). J Am Acad Dermatol. 2017 08; 77(2):372-374. Blauvelt A, Papp KA, Lebwohl MG, Green LJ, Hsu S, Bhatt V, Rastogi S, Pillai R, Israel R. PMID: 28711089.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    32. Randomized, Double-Blind Trial of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain. Pain Pract. 2017 07; 17(6):820-828. Rauck R, Slatkin NE, Stambler N, Harper JR, Israel RJ. PMID: 27860208.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    33. Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin. Antimicrob Agents Chemother. 2017 01; 61(1). DuPont HL, Wolf RA, Israel RJ, Pimentel M. PMID: 27795384; PMCID: PMC5192100.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    34. An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas. J Minim Invasive Gynecol. 2016 Mar-Apr; 23(3):303-8. Parker W, Berek JS, Pritts E, Olive D, Kaunitz AM, Chalas E, Clarke-Pearson D, Goff B, Bristow R, Taylor HS, Farias-Eisner R, Fader AN, Maxwell GL, Goodwin SC, Love S, Gibbons WE, Foshag LJ, Leppert PC, Norsigian J, Nager CW, Johnson T, Guzick DS, As-Sanie S, Paulson RJ, Farquhar C, Bradley L, Scheib SA, Bilchik AJ, Rice LW, Dionne C, Jacoby A, Ascher-Walsh C, Kilpatrick SJ, Adamson GD, Siedhoff M, Israel R, Paraiso MF, Frumovitz MM, Lurain JR, Al-Hendy A, Benrubi GI, Raman SS, Kho RM, Anderson TL, Reynolds RK, DeLancey J. PMID: 26773577.
      View in: PubMed   Mentions: 3     Fields:    
    35. Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension. J Palliat Med. 2015 Jul; 18(7):593-600. Bull J, Wellman CV, Israel RJ, Barrett AC, Paterson C, Forbes WP. PMID: 25973526; PMCID: PMC4492709.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    36. Characterization of abdominal pain during methylnaltrexone treatment of opioid-induced constipation in advanced illness: a post hoc analysis of two clinical trials. J Pain Symptom Manage. 2011 Nov; 42(5):754-60. Slatkin NE, Lynn R, Su C, Wang W, Israel RJ. PMID: 22045373.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    37. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009 Jan-Feb; 7(1):39-46. Slatkin N, Thomas J, Lipman AG, Wilson G, Boatwright ML, Wellman C, Zhukovsky DS, Stephenson R, Portenoy R, Stambler N, Israel R. PMID: 19278178.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    38. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008 May 29; 358(22):2332-43. Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, Stambler N, Kremer AB, Israel RJ. PMID: 18509120.
      View in: PubMed   Mentions: 137     Fields:    Translation:HumansCTClinical Trials
    39. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. 2008 May; 35(5):458-68. Portenoy RK, Thomas J, Moehl Boatwright ML, Tran D, Galasso FL, Stambler N, Von Gunten CF, Israel RJ. PMID: 18440447.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    40. The relationship between physicians and industry: Faustian or symbiotic? Am J Obstet Gynecol. 2003 Jun; 188(6):1530-40. Israel R. PMID: 12824990.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. Evaluation of a large cohort of men presenting for a screening semen analysis. Fertil Steril. 2000 Mar; 73(3):595-7. Acacio BD, Gottfried T, Israel R, Sokol RZ. PMID: 10689019.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    Robert's Networks
    Concepts (123)
    Derived automatically from this person's publications.
    _
    Co-Authors (10)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _